Introduction of Probiotic-Based Sanitation in the Emergency Ward of a Children's Hospital During the COVID-19 Pandemic.
COVID-19
biological monitoring
cross infection
drug resistance
probiotics
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
16
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) represents a major threat to public health, especially in the hospital environment, and the massive use of disinfectants to prevent COVID-19 transmission might intensify this risk, possibly leading to future AMR pandemics. However, the control of microbial contamination is crucial in hospitals, since hospital microbiomes can cause healthcare-associated infections (HAIs), which are particularly frequent and severe in pediatric wards due to children having high susceptibility. We have previously reported that probiotic-based sanitation (PCHS) could stably decrease pathogens and their AMR in the hospital environment, reduce associated HAIs in adult hospitals, and inactivate enveloped viruses. Here, we aimed to test the effect of PCHS in the emergency room (ER) of a children's hospital during the COVID-19 pandemic. Conventional chemical disinfection was replaced by PCHS for 2 months during routine ER sanitation; the level of environmental bioburden was characterized before and at 2, 4, and 9 weeks after the introduction of PCHS. Microbial contamination was monitored simultaneously by conventional culture-based CFU count and molecular assays, including 16S rRNA NGS for bacteriome characterization and microarrays for the assessment of the resistome of the contaminating population. The presence of SARS-CoV-2 was also monitored by PCR. PCHS usage was associated with a stable 80% decrease in surface pathogens compared to levels detected for chemical disinfection (
Sections du résumé
Background
UNASSIGNED
Antimicrobial resistance (AMR) represents a major threat to public health, especially in the hospital environment, and the massive use of disinfectants to prevent COVID-19 transmission might intensify this risk, possibly leading to future AMR pandemics. However, the control of microbial contamination is crucial in hospitals, since hospital microbiomes can cause healthcare-associated infections (HAIs), which are particularly frequent and severe in pediatric wards due to children having high susceptibility.
Aim
UNASSIGNED
We have previously reported that probiotic-based sanitation (PCHS) could stably decrease pathogens and their AMR in the hospital environment, reduce associated HAIs in adult hospitals, and inactivate enveloped viruses. Here, we aimed to test the effect of PCHS in the emergency room (ER) of a children's hospital during the COVID-19 pandemic.
Methods
UNASSIGNED
Conventional chemical disinfection was replaced by PCHS for 2 months during routine ER sanitation; the level of environmental bioburden was characterized before and at 2, 4, and 9 weeks after the introduction of PCHS. Microbial contamination was monitored simultaneously by conventional culture-based CFU count and molecular assays, including 16S rRNA NGS for bacteriome characterization and microarrays for the assessment of the resistome of the contaminating population. The presence of SARS-CoV-2 was also monitored by PCR.
Results and conclusions
UNASSIGNED
PCHS usage was associated with a stable 80% decrease in surface pathogens compared to levels detected for chemical disinfection (
Identifiants
pubmed: 35386291
doi: 10.2147/IDR.S356740
pii: 356740
pmc: PMC8978905
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1399-1410Informations de copyright
© 2022 Soffritti et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
PLoS One. 2014 Sep 26;9(9):e108598
pubmed: 25259528
Biomed Res Int. 2021 Jul 16;2021:5599724
pubmed: 34327231
Viruses. 2021 Nov 04;13(11):
pubmed: 34835033
Ann Ig. 2015 Nov-Dec;27(6):799-807
pubmed: 26835794
Bull World Health Organ. 2020 Jul 1;98(7):442-442A
pubmed: 32742026
Infect Control Hosp Epidemiol. 2018 Jan;39(1):1-11
pubmed: 29249216
Lancet Microbe. 2020 Aug;1(4):e146
pubmed: 33521712
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
BMC Infect Dis. 2006 Aug 16;6:130
pubmed: 16914034
PLoS One. 2018 Jul 12;13(7):e0199616
pubmed: 30001345
Science. 2020 Apr 10;368(6487):146-147
pubmed: 32273461
Int J Infect Dis. 2015 Feb;31:31-4
pubmed: 25528484
Antibiotics (Basel). 2021 Dec 29;11(1):
pubmed: 35052912
Antibiotics (Basel). 2018 Dec 14;7(4):
pubmed: 30558235
Int J Mol Sci. 2019 Mar 27;20(7):
pubmed: 30934725
Environ Res. 2020 Sep;188:109916
pubmed: 32846656
Infect Drug Resist. 2019 Feb 27;12:501-510
pubmed: 30881055
Environ Res. 2021 Feb;193:110559
pubmed: 33275925
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):9202-9207
pubmed: 32965015
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27799211
Euro Surveill. 2013 Jan 10;18(2):
pubmed: 23324427
Childs Nerv Syst. 2018 Oct;34(10):1865-1870
pubmed: 30121831
Clin Infect Dis. 2007 Oct 15;45(8):992-8
pubmed: 17879913
Pathogens. 2021 May 17;10(5):
pubmed: 34067889
Adv Exp Med Biol. 2019;1214:79-91
pubmed: 31321750
Am J Infect Control. 2013 May;41(5 Suppl):S6-11
pubmed: 23622751
Microorganisms. 2019 Dec 16;7(12):
pubmed: 31888282
Elife. 2021 Feb 16;10:
pubmed: 33588991
PLoS One. 2016 Feb 17;11(2):e0148857
pubmed: 26886448
Lancet. 2011 Jan 15;377(9761):228-41
pubmed: 21146207